Massaccesi M, Boldrini L, Piras A, Stimato G, Quaranta F, Azario L, Mattiucci G C, Valentini V
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italy.
Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy.
Tech Innov Patient Support Radiat Oncol. 2020 Mar 2;14:11-14. doi: 10.1016/j.tipsro.2020.02.003. eCollection 2020 Jun.
The possibility of intentionally triggering non targeted effects (NTEs) using spatially fractionated radiotherapy (SFRT) alone or combined with immunotherapy is an intriguing and fascinating area of research. Among different techniques for SFRT, stereotactic body radiotherapy targeting exclusively the central hypoxic segment of bulky tumors, (SBRT-PATHY) might trigger immunogenic cell death more efficiently. This in silico study aims to identify the best possible dosimetric trade-off for prescribing SFRT with volumetric modulated arc (VMAT) based stereotactic radiotherapy (SRT).
Eight spherical volumes defined "Gross Tumor Volumes" (GTVs) were generated with diameters of 3-10 cm (with incremental steps of 1 cm), simulating tumor lesions. The inner third part of each GTV (GTV) was selected to simulate the central hypoxic area and a ring structure was derived around it to simulate the tumor periphery (GTV). Volumetric modulated arc radiation treatment (VMAT) plans were calculated to deliver a single fraction of 10 Gy to each GTV with different dose prescription methods: target mean and isodose driven (40, 50, 60, 70, 80 and 90%).The volume of GTV receiving less than 2 Gy was recorded as dosimetric performance indicator.
56 possible dosimetric scenarios were analyzed. The largest percentage of GTV spared from the dose of 2 Gy was achieved with dose prescription methods to the 70% isodose line for lesions smaller than 6 cm (range 42.9-48.4%) and to the target mean for larger ones (range 52.9-64.5%).
Optimizing the dose prescription method may reduce the dose to tumor periphery in VMAT-based SFRT, thus potentially sparing tumor infiltrating immune cells. The optimal method may vary according to the size of the lesion. This should be taken into account when designing prospective trials using SFRT.
单独使用立体定向分割放疗(SFRT)或联合免疫疗法有意触发非靶向效应(NTEs)的可能性是一个有趣且引人入胜的研究领域。在不同的SFRT技术中,专门针对大体积肿瘤中央缺氧部分的立体定向体部放疗(SBRT - PATHY)可能更有效地触发免疫原性细胞死亡。这项计算机模拟研究旨在确定基于容积调强弧形放疗(VMAT)的立体定向放疗(SRT)中处方SFRT的最佳剂量权衡。
生成八个定义为“大体肿瘤体积”(GTVs)的球形体积,直径为3 - 10厘米(以1厘米的增量步长),模拟肿瘤病变。选择每个GTV的内三分之一部分模拟中央缺氧区域,并在其周围衍生出一个环形结构模拟肿瘤周边(GTV)。计算容积调强弧形放射治疗(VMAT)计划,以不同的剂量处方方法向每个GTV单次给予10 Gy:靶区平均剂量和等剂量线驱动(40%、50%、60%、70%、80%和90%)。记录接受小于2 Gy剂量的GTV体积作为剂量学性能指标。
分析了56种可能的剂量学方案。对于小于6厘米的病变,在70%等剂量线的剂量处方方法下,GTV免受2 Gy剂量的最大百分比得以实现(范围为42.9 - 48.4%);对于较大病变,则在靶区平均剂量处方方法下实现(范围为52.9 - 64.5%)。
优化剂量处方方法可能会降低基于VMAT的SFRT中肿瘤周边的剂量,从而有可能使肿瘤浸润免疫细胞免受照射。最佳方法可能因病变大小而异。在设计使用SFRT的前瞻性试验时应考虑到这一点。